Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, Scott Wilson, Luigi Salemme, Antonio De Donato, Angela Lombardi, Antonio Rainone, Luigi Nunziata, Stanislovas S. Jankauskas, Tullio Tesorio, Germano Guerra, Urna Kansakar, Pasquale Mone

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.

Original languageEnglish (US)
Pages (from-to)1800-1809
Number of pages10
JournalHypertension
Volume80
Issue number9
DOIs
StatePublished - Sep 1 2023

Keywords

  • cardiology
  • endocrinology
  • frailty
  • geriatrics
  • metabolism
  • nephrology
  • pharmacology

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart'. Together they form a unique fingerprint.

Cite this